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Abstract From the earliest stages of embryonic develop-
ment, cells of epithelial and mesenchymal origin contribute
to the structure and function of developing organs.
However, these phenotypes are not always permanent, and
instead, under the appropriate conditions, epithelial and
mesenchymal cells convert between these two phenotypes.
These processes, termed Epithelial-Mesenchymal Transi-
tion (EMT), or the reverse Mesenchymal-Epithelial Transi-
tion (MET), are required for complex body patterning and
morphogenesis. In addition, epithelial plasticity and the
acquisition of invasive properties without the full commit-
ment to a mesenchymal phenotype are critical in develop-
ment, particularly during branching morphogenesis in the
mammary gland. Recent work in cancer has identified an
analogous plasticity of cellular phenotypes whereby epithelial
cancer cells acquire mesenchymal features that permit escape
from the primary tumor. Because local invasion is thought to
be a necessary first step in metastatic dissemination, EMTand
epithelial plasticity are hypothesized to contribute to tumor
progression. Similarities between developmental and onco-
genic EMT have led to the identification of common
contributing pathways, suggesting that the reactivation of
developmental pathways in breast and other cancers con-
tributes to tumor progression. For example, developmental
EMT regulators including Snail/Slug, Twist, Six1, and Cripto,
along with developmental signaling pathways including TGF-
β and Wnt/β-catenin, are misexpressed in breast cancer and
correlate with poor clinical outcomes. This review focuses on
the parallels between epithelial plasticity/EMT in the mam-
mary gland and other organs during development, and on a
selection of developmental EMT regulators that are mis-
expressed specifically during breast cancer.
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Introduction
The evolution of multicellular organisms permitted the
development of specialized cell types and the diversifica-
tion of cellular phenotypes. One of the most primitive
divergences in cell phenotype in early organisms is the
distinction between epithelial and mesenchymal cells.
Epithelial cells provide cell-cell cohesion essential to
maintaining the integrity of the multicellular organism and
function as a critical barrier necessary for establishing a
regulated internal environment, independent from the
external environment [1]. In mammals, epithelialization of
the developing embryo occurs early during compaction of
the blastula [2, 3]. However, the development of more
complex body structures and functions requires the flexi-
bility afforded by another cell type, the mesenchymal cell.
Shortly after the epithelialization of the blastula, the
primary mesenchyme is formed during gastrulation, pro-
viding the first distinction between epithelial and mesen-
chymal phenotypes [4]. Cells exhibiting a mesenchymal
phenotype provide support and structure to the epithelial
cells particularly through the production of an extracellular
matrix and, unlike the rather confined and immobile
epithelial cell, are highly motile and invasive [5]. From
the evolution of primitive trilaminar body patterns to the
complex development and organogenesis of mammals,
epithelial and mesenchymal cell phenotypes are a basic
feature of normal development and physiology. However,
depending on the cell type and its particular environment,
epithelial and mesenchymal cell phenotypes are not static
and instead can be highly dynamic. Interconversion
between epithelial and mesenchymal cell phenotypes,
processes termed Epithelial-Mesenchymal Transition
(EMT) and the reverse Mesenchymal-Epithelial Transition
(MET), provides additional flexibility particularly during
embryogenesis, but also permits dynamic cellular remodel-
ing during wound healing and regeneration of fully
differentiated tissues [1, 6].
EMT, and the reverse process MET, have both been
thoroughly studied in mammalian development, where
numerous embryonic events and developing organs depend
on the switch between epithelial and mesenchymal pheno-
types including gastrulation [4], neural crest formation [7],
palatogenesis [8], heart valve formation [9], nephrogenesis
[10] and myogenesis [11]. While EMT is a critical normal
process during development and wound healing, recently
properties of EMT have been implicated in human
pathology, including fibrosis and cancer metastasis [12].
Not surprisingly, many of the same signaling pathways and
transcription factors important to physiologic instances of
EMT are also activated during pathologic EMT. While in
the adult, a quiescent epithelium does not typically exhibit
features of EMT. However, in the right context, either due
to an injurious insult or the genetic and environmental
perturbations of cancer, the epithelium may become
activated and primed for induction of epithelial plasticity
and EMT. Particularly in cancer, parallels with normal
development have been well established [13, 14]. The
implication of this observation is that cancer cells may
readily reactivate developmental properties out of context
in the adult, which then contribute to tumorigenesis via
inducing accelerated proliferation, resistance to apoptosis
and evasion of senescence. This idea extends beyond tumor
formation; the reactivation of developmental programs such
as EMT could facilitate tumor cell invasion, spread and
metastasis, and therefore may also represent a major
mechanism of tumor progression. Consistent with this
hypothesis, numerous signaling pathways and transcription
factors identified as critical mediators of developmental
EMT have also been implicated in oncogenic EMT and in
tumor progression.
Interestingly, the induction of a complete EMT is not the
only mechanism by which epithelial cells can migrate and
spread during development. In addition to EMT, epithelial
cell plasticity has also been observed in a process termed
collective migration. This process entails the movement of
epithelial cells as a group that is both physically and
functionally connected [15]. Collective migration has been
identified as a critical cellular process particularly during
mammary gland branching morphogenesis [16], intestinal
epithelial differentiation [17] and wound healing [18].
Although during collective migration epithelial cells main-
tain cell-cell junctions, many properties of collective
migration parallel changes observed during EMT, including
alteration of apico-basal polarity, modification of the
extracellular matrix and the acquisition of an invasive and
motile phenotype [15]. The similarities between EMT and
collective migration suggest that the transition between
epithelial and mesenchymal cell phenotypes may not
always represent two absolute and independent cellular
states, but instead a continuous spectrum of epithelial and
mesenchymal properties. This theory is particularly attrac-
tive in the context of cancer, which typically lacks the
coordinated and orderly induction of a complete EMT.
Instead, in cancer, the highly variable environmental cues
coupled with genetic heterogeneity of the tumor may lead
to varying degrees of epithelial plasticity and reactivation of
developmental migratory programs, resulting in the induction
of single cell and/or collective cell migration. In this review,
we will discuss EMTand epithelial plasticity in development,
as well as the evidence for reactivation of these developmen-
tal programs in cancer progression and metastasis. We will
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then focus on select examples of developmental EMT
regulators which have been identified as critical contributors
to breast cancer progression specifically.
Defining Epithelial-Mesenchymal Transition (EMT)
in Development and in Cancer
During developmental EMT, a highly coordinated and
specific series of events define the transition between
epithelial cells and mesenchymal cells (Fig. 1) [1]. EMT
begins with the loss of apico-basal polarity as tight junctions
dissolve, permitting intermingling of apical and basolateral
membrane components [19]. Additional cell-cell junctions
including adherens and gap junctions begin to disassemble
and the underlying basement membrane is degraded [20].
Cell surface proteins like E-cadherin and integrins, that
mediate epithelial connections to neighboring cells and the
basement membrane, respectively, are replaced by N-
cadherin and integrins that provide more transient adhesive
properties priming the cell for the mesenchymal phenotype.
Additionally, cytoskeletal elements are reorganized and the
peripheral actin cytoskeleton is replaced by stress fibers,
whereas cytokeratin intermediate filaments are replaced by
vimentin. Together, these changes transition the cell from a
cuboidal to a spindle shape. Finally, the cell acquires the
ability to invade and move into the extracellular matrix
devoid of any cell-cell contacts. Presumably during this
process the epithelial cells also acquire resistance to anoikis
and begin to respond to extracellular cues, directing the
migrating cells along highly specific routes to their
destination. Interestingly, upon arriving at their destination,
these mesenchymal cells may undergo the reverse process of
mesenchymal-epithelial transition (MET) [10]. Therefore,
over the course of development, progenitor cells may
undergo EMT or MET and some even undergo additional
rounds of EMT and MET, ultimately giving rise to the
precursor cells of numerous organs and tissues within the
developing embryo.
During development, the steps of EMT are well-defined
and typically accompanied by cell fate decisions, however
the EMT associated with cancer and fibrosis is less clearly
defined and specific to each pathology. While the basic
features of EMT are similar among the different conditions,
a recent series of reviews has proposed classifying EMT
into three different subtypes, based on the functional
consequences and biological context, in an attempt to better
reflect the distinctive properties of EMT in development.
These three types are developmental (Type I), fibrosis and
wound healing (Type II), and cancer (Type III) [21]. In
addition, biomarkers specific to each subtype of EMT and
also common to all subtypes have been defined [22].
Overall, EMT is characterized as a downregulation of
epithelial markers, particularly E-cadherin, and an upregu-
lation of mesenchymal markers, particularly vimentin or
fibronectin, accompanied by an increase in cell migration
and invasion.
In cancer, features of EMT have been observed in breast
[23], ovarian [24], colon [25], and esophageal [26] cancer
models. Oncogenic EMT is associated with loss of apico-
basal polarity [27], disintegration of tight junctions [28] and
adherens junctions, cytoskeletal changes, including the
downregulation of cytokeratins and the upregulation of
vimentin [29], and the acquisition of a motile and invasive
phenotype paralleling changes observed during develop-
mental EMT. Consistent with the hypothesis that develop-
mental programs are reactivated during tumorigenesis and
contribute to tumor progression, numerous EMT regulators
in development are also inappropriately expressed in
human cancer and correlate with features of EMT, albeit
Figure 1 EMT and Epithelial Plasticity. During EMT, epithelial cells
lose their apico-basal polarity. Tight junctions which typically
maintain apico-basal polarity dissolve allowing the mixing of apical
and basolateral membrane proteins. Adherens and gap junctions are
disassembled and cell surface proteins such as E-cadherin and
epithelial-specific integrins (green) are replaced by N-cadherin and
integrins specific to extracellular components (blue). The actin
cytoskeleton is remodeled into stress fibers which accumulate at areas
of cell protrusions. The epithelial intermediate filaments, cytokeratins,
are replaced by vimentin. Meanwhile, the underlying basement
membrane is degraded and the cell invades and moves into the
surrounding stroma, devoid of cell-cell contacts.
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with less order and coordination than observed in develop-
mental EMT [30]. Numerous inducers of EMT in cancer
cell lines have been identified including Transforming
Growth Factor-β (TGF-β) [31], Wnt [32], Snail/Slug [33,
34], Twist [35] and Six1 [36, 37], and these oncogenic
EMT inducers are also critical during developmental EMT
[9, 38–40]. These regulators will be discussed more below.
In the context of epithelial cancer, EMT provides a
mechanism for tumor cells to leave the primary tumor and
invade into the local tissue and blood vessels, setting the
stage for metastatic spread (Fig. 2). Therefore, EMT is
hypothesized to contribute to tumor progression, and
indeed clinical evidence suggests that regulators of EMT
in cancer cells correlate with poor patient outcomes and
tumor aggressiveness [41, 42]. However, unlike develop-
mental EMT, which typically proceeds stepwise under the
tight control of morphogenic signals and generally corre-
lates with a cell fate change, oncogenic EMT occurs in the
context of unpredictable genetic changes present in the
tumor cells, as well as an abnormal local tumor environ-
ment. Therefore, EMT in cancer is much more difficult to
predict and observe in vivo, since only a subset of tumor
cells may undergo EMT at any one time. In colon cancer,
cells exhibiting properties of EMT have been specifically
localized to the periphery of the tumor where they are
primed to undergo EMT likely by exposure to cytokines
and an extracellular milieu that promotes EMT [25]. Much
of the recent work on inducers of EMT has utilized tissue
culture models to assess the epithelial and mesenchymal
phenotype of cancer cell lines. However, numerous EMT
inducers characterized in cell culture systems can initiate
metastatic spread in animal models, and in fact correlate with
poor prognosis in human cancer [35, 37]. Therefore, mis-
expression of EMT regulators in cancer appears to have
clinical significance. Importantly, the reactivation of develop-
mental programs in cancer offers the potential to identify new
drug targets that inhibit the metastatic process and may also
be specific to the cancer, leaving the fully differentiated adult
epithelium unaffected.
Examples of Developmental EMT
During development the first instance of EMT occurs during
gastrulation, giving rise to the primary mesenchyme and the
formation of the three primitive germ layers (Fig. 3a).
Signaling molecules emanating from the Spemann-Mangold
organizer, a region of the embryo critical for axis formation
and neuralization, act on cells at the primitive streak to induce
EMT and to specify cell fate [43]. During gastrulation, the
first observable evidence of EMT is the breakdown of the
basement membrane underlying the epiblast [44]. Subse-
quently, the action of Fibroblast Growth Factor (FGF) on the
cells in the primitive streak results in an upregulation of the
zinc finger transcription factor Snail, repressing E-cadherin
and destabilizing cell-cell junctions [45]. Additional signals
Figure 2 EMT promotes metastasis by enhancing local invasion.
During primary tumor formation, the genetic and epigenetic changes
in the tumor cells coupled with alterations in the tumor microenvi-
ronment promote EMT. EMT and epithelial plasticity enable the tumor
cells to de-adhere from their neighboring cells, invade through the
underlying basement membrane and move into the surrounding tissue
either as single cells (blue) or as clusters (light blue) of cells. This
local invasion sets the stage for metastatic dissemination and spread to
the draining lymph nodes. In addition, migration of single cells and
potentially clusters of cells also can access the bloodstream leading to
hematogenous spread of tumor cells and the development of distant
metastatic disease.
120 J Mammary Gland Biol Neoplasia (2010) 15:117–134
complete the induction of EMT leading to ingression of the
cells within the primitive streak. Ingressing cells then either
undergo MET and give rise to the endoderm or remain
mesenchymal and give rise to the mesoderm.
As development progresses, another example of EMT
occurs in cells of the neuroectoderm that generate a second
population of primary mesenchymal cells as the neural tube
closes (Fig. 3b). As neurulation occurs in vertebrate develop-
ment, cells near the junction of the neuroectoderm and the
embryonic ectoderm undergo EMT, generating a migratory
neural crest cell population [7]. After delamination and
migration throughout the developing embryo, these cells
give rise to various cell types and tissue structures including
facial and cervical structures, the neurons of the peripheral
nervous system, pigment cells and the cells of the adrenal
medulla. The molecular basis of neural crest EMT includes
expression of the E-cadherin repressor, Snail [46]. Induction
of Snail likely is under control of converging signals
including Bone Morphogenetic Protein (BMP), Nodal, Wnt
and FGFs [47]. An interesting aspect of neural crest
migration revolves around the extensive cell-cell interactions
that occur after EMT and the delamination from the
ectoderm. In fact, the migration of neural crest cells has been
described as collective migration, since the mesenchymal
cells transiently interact through both physical and bio-
chemical interactions, thereby modulating neighboring cell
migration [48]. This interaction between neighboring neural
crest cells allows them to move in close proximity as an
organized stream.
In addition to gastrulation and neural crest formation,
EMT is also critical in the development of other organs
including the cardiac heart valves, the skeletal muscle and
the palate. During heart development, endocardial cells
activated by factors secreted by the adjacent myocardium
undergo EMT and invade through the basement membrane
and into the cardiac jelly. The cells remain here as
mesenchymal cells of the cardiac cushion and mediate
development of the cardiac heart valves [9]. In the context
of the endocardium, TGF-β [49], BMP [50], β-catenin
[51], Msx1/2 [52] and Slug [53], among other factors,
regulate endocardial EMT. EMT is also critical during myo-
genesis, particularly as the muscle precursor cells delaminate
from the dermomyotome. The dermomyotome is an epithe-
lial structure derived from the paraxial mesoderm. Pax3
expression is an important determinant of muscle cell
progenitors in the dermomyotome [54], and interacts with
a conserved gene network including Six, Eya and Dach
proteins to direct muscle precursor development and migra-
tion [40]. Upon induction of EMT, the muscle precursors
invade into the developing limbs and differentiate into
mature muscle cells. Interestingly, although the EMT
associated with myogenesis has not been comprehensively
studied, the genes identified as important in this EMT have
not been implicated in other classical EMT processes such
as gastrulation, neural crest formation, heart valve formation
or palatogenesis. While the precise reason for this difference
remains unknown, it suggests that the EMT associated with
muscle development may be orchestrated in a slightly
different manner than other developmental EMTs, potentially
setting the stage for the muscle differentiation program.
Future studies on the early events of myogenic precursor for-
mation will investigate the nature of this EMT. Interestingly,
during palatogenesis the function of EMT is also somewhat
different than other developmental EMTs. Instead of giving
rise to a migratory mesenchymal cell type while maintaining
the epithelial source, during palatal fusion the epithelial tissue
within the medial edge epithelium (MEE) collapses, giving
rise to a continuous mesenchymal tissue and a seamless
Figure 3 Developmental EMT. a During gastrulation, ectodermal
cells (yellow) at the primitive streak undergo EMT (blue) as a result of
signals produced by the Spemann-Mangold organizer. These cells
ingress through the primitive streak and migrate into the underlying
tissue. The newly ingressed cells either remain mesenchymal
becoming the primary mesoderm (red) or undergo MET forming the
endoderm (green) and together establish the trilaminar embryo. b The
neural crest cells (blue) are formed from an EMT of cells at the border
of the embryonic ectoderm and the neuroectoderm during closure of
the neural tube. After invading from their site of origin, neural crest
cells migrate throughout the developing embryo giving rise to diverse
tissue including craniofacial structure, the adrenal medulla and the
peripheral nervous system.
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palate [8]. Similar to other examples of developmental EMT,
the molecular regulators of EMT in the palate include TGF-β
[8], Snail [38] and Twist [55].
Interestingly, the reverse process, MET, is also observed
during development, particularly in nephrogenesis as the
ureteric bud invades the metanephric mesenchyme. Upon
induction, the metanephric mesenchyme condenses around
the invading bud and undergoes MET. The Six/Eya proteins
are also implicated in the maintenance of the metanephric
mesenchyme and the prevention of precocious differentia-
tion and MET [56]. Six2, which is downstream of Six1 in
the developing kidney [57], is critical in the decision to
differentiate or self-renew. Downregulation of Six2 is
linked to MET, and its presence is believed to be required
for the maintenance of early nephrogenic progenitor cells
[58]. Therefore EMT and MET are critical in the develop-
ment of multiple organs, and utilize diverse and tissue
specific molecular mechanisms.
Defining Epithelial Plasticity and Partial EMT
in Development
During development, EMT provides the flexibility to
convert between different cell phenotypes that are required
for proper morphogenesis as discussed above. However, the
development and morphogenesis of numerous tissues
during embryogenesis requires epithelial plasticity that
differs somewhat from classical EMT, and that parallels
changes seen in cancer. However, similar to EMT, these
processes require perturbations of the normally static nature
of an epithelium and the acquisition of properties of invasive
and motile cells. In particular, epithelial plasticity is essential
during branching morphogenesis that occurs during develop-
ment of numerous organs including the kidney, lung,
mammary gland and salivary gland [59]. Branching mor-
phogenesis is a complex morphogenic mechanism by which
a tubular epithelial structure bifurcates in an iterative process
to generate an intricate ductal tree. During branching
morphogenesis, tip cells located at the leading edge of the
elongating epithelial tube undergo morphologic and cellular
changes in response to extracellular signals, including FGFs,
culminating in the bifurcation of the epithelial tube [59].
While distinct from a complete EMT, during branching
morphogenesis the tip epithelial cells transiently exhibit
mesenchymal features, ranging from loss of apico-basal
polarity, degradation of the basement membrane, and
increased cell protrusions and mesenchymal marker expres-
sion, depending on the tissue [59]. The plasticity of
epithelial cells during development suggests that in the
broadest sense, the difference between epithelial and
mesenchymal cells may be more of a continuous spectrum
rather than two independent cell states.
In addition to developmental examples of partial EMT,
wound healing also exhibits features of epithelial plasticity.
For example, collective migration of the sheet of epithelial
cells at the edge of the wound results in the closing of the
injury. The leading cells maintain adhesion to surrounding
cells and therefore do not undergo a full EMT. However,
they exhibit mesenchymal properties including directed cell
movement, development of cell protrusions and loss of
apico-basal polarity (Fig. 4) [15]. Overall, these observa-
tions suggest that epithelial plasticity encompasses a
continuum from epithelial cells bound in a continuous
uninterrupted cell sheet to an isolated, spindle-shaped
mesenchymal cell that has undergone a complete EMT.
During development, healing and cancer, epithelial cells can
undergo varying degrees of epithelial plasticity. These
changes in epithelial plasticity permit a dynamic cell
migratory response dependent on the constitution of the cell,
its gene expression, and on input from the local environment.
Epithelial Plasticity in the Mammary Gland
The mammary gland develops in three distinct stages
consisting of an embryonic stage of rudimentary gland
development, a pubertal stage of ductal elongation and
branching, and a pregnancy stage of alveolar differentiation
and tertiary ductal branching [60]. Mammary gland
development begins during mid-gestation as the mammary
lines form and placodes develop along these lines. The
placodes invaginate into the underlying subdermal stroma
forming the mammary bud. As embryogenesis continues,
the mammary bud begins to invade into the surrounding
adipose tissue producing a rudimentary mammary gland
that is arrested at this stage until puberty.
During puberty, branching morphogenesis coupled with
ductal elongation fills the mammary fat pad and arborizes
the ductal tree, preparing the mammary gland for pregnancy
associated alveolar development and lactation (Fig. 5a). As
puberty progresses, the rudimentary gland begins to
elongate with the formation of terminal end buds (TEB)
[60]. The TEB is a multi-layered epithelial structure at the
forefront of ductal development which gives rise to the
bilayered mammary ducts that consist of luminal epithelial
and myoepithelial cells, and also is the predominant site of
branching during puberty [61]. Interestingly, the TEB
bifurcates under the regulation of a number of extracellular
cues known to regulate epithelial plasticity and induce
EMT, including epidermal growth factor (EGF), Hepatocyte
Growth Factor/Scatter Factor (HGF/SF), and the activity of
proteases such as the matrix metalloproteinases (MMPs)
[62]. While the exact molecular mechanisms of branching
in the mammary gland are still being elucidated, it is clear
that the combination of biochemical signals along with the
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physical constraints of the developing mammary gland
direct branching. Unlike other branching organs, the
elongation of the ducts depends on proliferation within
the TEB instead of the protrusive activity of the cap cells
[63]. However, even though the cap cells do not exhibit
protrusions characteristic of an invasive cell phenotype and
do not lose their cell-cell adhesions, these cells still exhibit
signs of epithelial plasticity. Such signs include, amongst
other things, the loss of apico-basal polarity, as determined
by the lack of specific localization of β-catenin to the
basolateral domain and atypical protein kinase C-ζ to the
apical domain [16]. In addition, cells of the TEB secrete
extracellular proteases, including MMP3, coincident with a
thinning of the basement membrane [62]. They further
activate the EMT inducing Msx2/Cripto-1 pathway [64, 65].
As additional evidence of epithelial plasticity, the cells of
the TEB also likely exhibit a different complement of
integrins and extracellular matrix receptors compared to
quiescent mammary epithelium, since numerous integrin
knockout mice, including α2, α3 and β1, exhibit decreased
branching [62]. These results suggest that at the site of
branching, mammary epithelial cells display a significant
alteration of their interaction with the extracellular matrix.
The existence of epithelial plasticity during branching
morphogenesis has been confirmed in organotypic cultures
where mammary epithelial cells treated with EGF or HGF
begin to branch. Furthermore, cells at the sites of branching
activate the promoter of the mesenchymal marker, vimentin,
and express MMP3, an inducer of EMT [66]. Additionally,
microarray analysis of gene expression in the TEB identified
the known EMT regulators, Snail and Twist, as significantly
increased in the TEB compared to the mature ducts [67].
These data support the hypothesis that regulators of EMT
induce epithelial plasticity during mammary gland develop-
ment. Overall, while mammary epithelial cells of the TEB
do not exhibit the hallmarks of a complete EMT, these cells
acquire multiple features of epithelial plasticity.
EMT in Breast Cancer
The prognosis of breast cancer patients is tightly correlated
with the degree of spread beyond the primary tumor [68].
However the mechanisms by which epithelial tumor cells
escape from the primary tumor and colonize a distant site is
not entirely understood. Recent work in breast cancer and
other cancers has postulated EMT as a potential mechanism
by which epithelial tumor cells acquire a more motile and
invasive phenotype and escape from the primary tumor
[69]. In breast cancer, similar to other cancers, EMT rarely
Figure 4 Epithelial Plasticity during development and wound healing.
Sheet movement is a form of collective cell migration that occurs during
wound healing. Cell polarity is determined by the edge of the sheet
where cells of the leading edge maintain adhesion to neighboring cells
while directing the movement of the sheet to close the wound. These
leading or pioneer cells (light blue) do not undergo a full EMT but
exhibit mesenchymal features such as directed movement, develop-
ment of cell protrusions, and loss of apico-basal polarity. However, the
epithelial phenotype is maintained and completely regained once the
wound or gap is closed. Arrows portray directional movements.
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occurs homogenously across the whole tumor. The excep-
tions include diffuse lobular carcinoma, where E-cadherin
is lost uniformly across the tumor and gene expression
profiles identify genes involved in EMT including upregu-
lation of fibronectin and collagen type I and III [70].
Another exception is that of the sarcomatoid tumor of the
breast, also referred to as spindle-cell carcinoma tumors,
which display a clear mesenchymal and spindle cell
phenotype [69] while still retaining keratin expression and
evidence of an epithelial origin [71]. However, based on the
expression of EMT markers, recent evidence suggests that
EMT also occurs in a more local manner at the invasive
front of the tumor [72], and that such a localized EMT is no
less clinically significant than the EMTs mentioned above.
In this more limited example of EMT, the tumor cells are
primed to undergo EMT by genetic and epigenetic changes.
Then, with the proper extracellular inputs, including
activation of TGF-β and Wnt signaling at the leading edge
of the tumor coupled with the expression of EMT regulators
such as Snail/Slug/Twist, Cripto-1 and Six1, the cells
acquire a mesenchymal phenotype that permit them to
locally invade and escape from the primary tumor, setting
the stage for metastatic dissemination (Fig. 5b). However,
once the epithelial tumor cells undergo EMT, they may be
phenotypically indistinguishable from fibroblasts. As a
consequence, unequivocal evidence of EMT in most
cancers is lacking. The absence of pathologic evidence for
EMT at the secondary site, since most metastatic lesions
exhibit an epithelial phenotype, has also contributed to the
disbelief by some that EMT occurs in tumor progression.
Evidence for the role of EMT in cancer is complicated by
the fact that at the secondary site the metastatic cells likely
Figure 5 Parallels between normal mammary development and breast
cancer progression. a Mammary gland development begins during
embryogenesis resulting in a rudimentary ductal system. After onset of
puberty, ductal elongation and branching morphogenesis leads to
extension and arborization of the ductal tree. As the ducts extend
through the mammary fat pad, differentiation of precursor cells in the
TEB gives rise to the luminal and myoepithelial cells. In addition, cap
cells at the leading edge of the TEB exhibit features of epithelial
plasticity that are critical to the normal branching process (Inset).
During pregnancy, lobuloalveolar development and side branching
occur in preparation for lactation. b Breast cancer begins with the
primary lesion, however as breast cancer progresses, tumor cells
acquire an invasive and motile phenotype analogous to the epithelial
plasticity and EMT observed in development. The epithelial plasticity
and EMT permits local spread of tumor cells. Genes/pathways
implicated in EMT and epithelial plasticity and misexpressed in breast
cancer progression include Cripto-1, Snail/Slug/Twist, Six1, Wnt and
TGF-β signaling (Inset). Local invasion of both single cell and
collective migration of the tumor cells sets the stage for metastatic
dissemination to distant organ sites in late stage breast cancer.
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undergo a reversion or MET, permitting colonization of the
distant site. Therefore in the course of cancer progression,
EMT is a transient and reversible process. However, the
recent use of cell fate mapping of epithelial tumor cells in
the Whey Acidic Protein (WAP)-Myc transgenic mice
provides direct evidence of EMT in the local invasion of
tumor cells in breast cancer [23], finally putting an end to
the argument as to whether EMT can occur in mammary/
breast cancer. Furthermore, recent evidence obtained from
microarray analysis of breast tumors support the hypothesis
that certain types of breast cancer cells are primed to
undergo EMT and spread. For instance, the basal or triple
negative breast cancer subtype exhibits an aggressive
phenotype and also correlates with the poorest clinical
outcomes [73]. Markers of EMT are preferentially dis-
played in the basal subtype as well as in a newly recognized
claudin-low subtype, linking EMT with the molecular
subtype of a tumor [74, 75]. When breast cancer cells lines
are similarly classified, those cells classified as basal B, a
subdivision of the basal cluster, also display a mesenchymal
phenotype [76]. This work supports the existence of EMT in
breast cancer and suggests that the cells undergo MET at the
site of metastatic colonization. This hypothesis underscores
the necessary plasticity of cancer cells and suggests that
instead of a permanent mesenchymal phenotype, migrating
cancer cells likely exhibit epithelial plasticity that is reversible
and dependent on the local microenvironment.
Recently, a novel hypothesis for the role of EMT in cancer
progression has been proposed, whereby epithelial and
mesenchymal cells cooperate during metastatic dissemina-
tion, potentially eliminating the need for MET at the distant
site [77]. According to this hypothesis, neither epithelial nor
mesenchymal cells alone are sufficient to induce metastatic
spread, however, when combined these cells cooperate to
induce metastases. Evidence supporting this theory is
derived from a model where EMT was induced through
expression of p12CDK2-AP1 in a keratinocyte cell line.
Neither control cells nor cells induced to undergo EMT by
p12 expression alone were competent to develop metastases
after subcutaneous injection in a xenograft model of
squamous cell carcinoma. However, tumors derived from
cells that had undergone EMT did exhibit local invasion and
evidence of intravasation into the blood stream. When the
same control cells and cells induced to undergo EMT were
tested in an experimental metastasis model and injected
directly into the vein of mice, only the control cells that did
not undergo EMT could form lung metastases. However
unexpectedly, when a 1:1 mixture of control cells and cells
that had undergone EMTwere injected subcutaneously, lung
metastases developed that were composed solely of the
control cells [78]. These observations suggest that EMT is
necessary for metastasis, but that it is not sufficient, and that
it is the non-EMT cells that colonize distant tissues.
Similarly, the findings suggest that non-EMT cells are
necessary, but not sufficient for metastasis, and require cells
that have undergone EMT in order to gain access to the
circulation from the primary tumor [77]. To provide
conclusive evidence in support of this finding, however,
will require fate mapping the EMT and non-EMT cells and
following their phenotypic profile during the course of
metastatic spread. However, these results suggest that
cooperativity between cells of different phenotypes either
through direct interaction or a secreted signal may be an
important mechanism of metastatic spread.
In addition to the induction of EMT, which results in
single cell dissemination of tumor cells, collective migra-
tion of groups of tumor cells may also be a mechanism by
which cancer can spread [63]. Clinical evidence has
identified strands and columns of tumor cells in the
peritumoral tissue that appears to be migrating away from
the primary tumor as a collective group [79]. In addition,
growth of explanted tumors in three dimensional collagen
gels identified groups of cells detaching from the primary
tumor and invading into the surrounding matrix [80]. Most
recently, intra-vital, non-invasive imaging of tumor cell
migration and invasion has supported the role of collective
cell migration of tumor cells in vivo in a fibrosarcoma tumor
model which is also consistent with observations of collective
cell migration observed in a breast cancer xenograft mouse
model [81, 82]. Analogous to the collective migration seen
in mammary gland development and wound healing, the
combination of epithelial plasticity while still maintaining
adherence to neighboring cells appears to be another
mechanism of tumor spread. Interestingly, the dominant
mode of migration of a tumor may determine the preferred
site of metastatic spread. Whereas solitary movement of
tumor cells in vivo, particularly in cooperation with macro-
phages, directs tumor cells to the blood vessels resulting in
hematogenous dissemination [83, 84], collectively migrating
cells have been reported to result in lymphatic dissemination
[82]. Interestingly, TGF-β signaling, which induces EMT
and single cell migration, is necessary for intravasation,
extravasation and blood borne metastasis [82, 85]. In line
with this finding, inhibition of TGF-β signaling in a rat
mammary carcinoma model can inhibit single cell migra-
tion, but collective migration of tumor cells is maintained
and results in exclusively lymphatic metastases [82].
Together, these results suggest that the mode of migration
may determine the route of metastatic dissemination.
Somewhat surprisingly, although the major function of
EMT in tumor progression is believed to be the induction of
an invasive phenotype, EMT also elicits numerous other
features that likely contribute to tumor progression (Fig. 6).
For example, recent work has identified a correlation
between EMT and the induction of a tumor-initiating
phenotype that has been likened to a cancer stem cell
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[86]. The expression of multiple inducers of EMT in breast
cancer cell lines increases the tumor initiating cell popula-
tion as determined by cell surface markers, mammosphere
formation, and limited dilution tumor formation assays [36,
86]. The induction of a cancer stem cell-like phenotype is
predicted to provide a subset of tumor cells the ability to
self-renew and likely is a critical feature required for ultimate
colonization of a distant metastatic site. These results beg the
question as to whether EMT in cancer is transdifferentiation
of epithelial cells to mesenchymal cells, or rather dedifferen-
tiation to a more progenitor/stem-like phenotype that is
accompanied by an increased invasive ability. However, the
misexpression of EMT developmental regulators in cancer
suggests that these cancer cells may in fact be acquiring a
mesenchymal phenotype, rather than a less differentiated
phenotype. In addition to inducing a tumor-initiating cell
phenotype, regulators of EMT also influence cell survival,
specifically after treatment with chemotherapeutic agents [87,
88], as well as prevent oncogene-induced senescence [89],
both properties associated with tumor progression. These
data suggest that current therapies do not target the most
invasive, aggressive and tumor-initiating cells within a tumor.
Instead, the therapies may enrich for a more mesenchymal
phenotype. Indeed, recent evidence shows that this is the
case: therapies do select for more mesenchymal and cancer
stem cell-like cancer cells, pointing to a need for chemother-
apeutic agents that specifically target cells that have under-
gone EMTand display enhanced tumor-initiating capabilities
[90, 91]. This property of current therapies likely explains
the treatment failures associated with the basal/claudin-low
subtypes of breast cancer. For a more detailed review of the
clinical implications of EMT, please see the accompanying
review by Creighton and colleagues.
Finally, the induction of EMT not only regulates features
intrinsic to the tumor cells, but also regulates the tumor
cell’s interaction with its microenvironment, including the
immune cells. Tumor cells that have undergone EMT in
response to forced expression of Snail induce immunosup-
pressive cytokines and impair tumor surveillance mecha-
nisms [92]. Again, the ability of cells undergoing EMT to
evade the immune system by directly regulating it, more
than likely contributes to the aggressiveness of the tumor.
Overall, these results suggest that the induction of EMT is
not simply a migratory mechanism of local spread of tumor
cells from the primary site, but instead induces a compre-
hensive program of properties necessary for tumor progres-
sion. Additionally, these results reinforce the viability of
therapeutic agents that target regulators of EMT/tumor-
initiating cells, particularly those developmental EMT
regulators expressed de novo in cancer.
Molecular Pathways of Development Reactivated
in Breast Cancer
Recent work has identified numerous developmental
regulators of EMT that are misexpressed in breast cancer
and contribute to breast cancer progression. The spectrum
of EMT inducers implicated in breast cancer includes both
signaling pathways such as TGF-β, Wnt/β-catenin, and
Cripto, as well as transcription factors including Twist,
Snail/Slug, Lbx1, and Six1. In addition, recently non-
coding RNAs, including microRNAs, have been implicated
in EMT in cancer and development [93, 94]. For a more
detailed review of microRNAs in EMT, please see the
accompanying review by Goodall and colleagues.
Msx2/Cripto Pathway
During mammary gland development, numerous factors have
been implicated in branching morphogenesis. Interestingly, a
number of these factors have also been implicated in
oncogenic EMT during breast cancer progression, including
Cripto-1. Cripto, a member of the epidermal growth factor-
Cripto/FRL-1/Cryptic (EGF-CFC) family of proteins, is a
developmental regulator during early embryogenesis and a
cofactor for the TGF-β family ligand, Nodal. Cripto is
expressed at the primitive streak and Cripto-knockout mice
do not progress beyond early body patterning events due to a
deficiency in formation of the mesoderm suggesting a role for
Figure 6 The Functional Consequences of EMT. In addition to the
well-characterized role for EMT in local spread of tumor cells, induction
of EMT also correlates with numerous other properties including a
tumor-initiating cell phenotype, resistance to chemotherapy and
senescence, evasion of the immune system and induction of a basal
gene expression profile.
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Cripto in the early developmental cell movements and EMT
[95]. However, Cripto is also expressed in the epiblast
epithelium prior to gastrulation suggesting the Cripto likely
cooperates with other pathways and is not sufficient alone to
induce EMT [95]. In addition, Cripto is a developmental
regulator of branching morphogenesis in the mammary
gland. Cripto-1 expression is observed in the cap cells in the
terminal end buds of the mammary gland [96], and Mouse
Mammary Tumor Virus (MMTV)-Cripto transgenic mice
display increased mammary gland branching [97]. These
data suggest that Cripto is expressed in the cells displaying
epithelial plasticity during ductal branching and that its
misexpression increases branching. Additional work in vitro
confirms that Cripto overexpression in numerous mammary
epithelial cell lines can increase branching in three-
dimensional cultures, increase the invasive and migratory
properties of the cells, and induce an EMT [65]. Not only
can Cripto induce these properties of EMT in vitro, but its
misexpression is also sufficient to induce mammary tumor
formation in transgenic mice. Interestingly, MMTV-Cripto
transgenic mice develop tumors that display properties of
EMT including downregulation of E-cadherin and upregu-
lation of vimentin and N-cadherin [98]. Importantly,
transgenic mice expressing Cripto under the regulation of
the WAP promoter also develop mammary tumors and the
tumors that arise are of multiple histological subtypes
including glandular, papillary, adenosquamous, solid and
myoepithelioma [99]. The mixture of histologic subtypes
suggests that Cripto expression may not only induce an
EMT, but it may also induce a stem/progenitor-like
phenotype that would be consistent with other regulators
of EMT [86]. In support of a role for Cripto misexpression
in human breast cancer, increased Cripto expression has
been observed in 50% of ductal carcinoma in situ and an
even greater 80% of infiltrating ductal carcinoma [100].
Paralleling the observations from early embryonic develop-
ment, the expression of Cripto in breast cancer prior to the
acquisition of invasive properties suggests that Cripto
expression likely cooperates with other pathways to induce
an invasive phenotype and may prime the cells for EMT.
Together, these results establish Cripto as a significant
regulator of branching morphogenesis in the mammary
gland and demonstrate that misexpression of Cripto in breast
cancer models induces EMT. Importantly, Cripto misexpres-
sion correlates with advanced disease in human cancer,
reinforcing the significance of its aberrant expression in
breast cancer progression.
Recent work has begun to elucidate the potential
mechanism of Cripto misexpression and, not surprisingly,
another EMT regulator and mammary developmental gene,
Msx2, upregulates Cripto [64]. Under the regulation of
progesterone, the homeodomain protein Msx2 increases
lateral branching and transgenic mice expressing Msx2 in
the mammary gland also display increased branching
similar to what is observed with misexpression of Cripto
[101]. In the context of cancer, Msx2 induces EMT in vitro
in numerous cancer cell lines [64, 102]. Finally, analysis of
clinical human breast cancer samples revealed that Msx2
expression is specifically observed in the infiltrating cells of
the tumor that display an invasive phenotype [64].
Together, these data suggest that the developmental gene
network consisting of Msx2 and Cripto is activated and
likely contributes to mammary tumor progression. For a
more detailed discussion of Cripto and the role of EGF
signaling in EMT and breast cancer, please see the
accompanying review by Salomon and colleagues.
The E-cadherin Repressors Snail, Slug and Twist
The E-cadherin repressors, Snail and Slug, and the basic
helix-loop-helix transcription factor Twist, are also clear
examples of inappropriately expressed developmental regu-
lators in breast cancer. In the primitive streak, Snail is
expressed in response to FGF, resulting in the transcriptional
downregulation of E-cadherin and the induction of EMT
during gastrulation [45]. In mice lacking Snail, the cells of
the primitive streak begin to invade, however the EMT,
specifically the downregulation of E-cadherin, is incomplete.
The remaining cells maintain an epithelial phenotype
including apico-basal polarity and cell-cell adhesions [103].
In addition to gastrulation, the E-cadherin repressor proteins
are also expressed during other developmental EMT events
including palatal fusion (Snail and Twist) and neural crest
migration (Snail and Slug depending on the species) [7].
Most recently, microarray analysis of microdissected ter-
minal end buds in the mammary gland identified a
significant upregulation of the Snail and Twist transcripts
when compared to their expression in mature ducts,
suggesting that these developmental EMT regulators may
also regulate epithelial plasticity in the mammary gland [67].
Snail, Slug and Twist are also significant inducers of EMT in
cancer cells and repress E-cadherin expression [35, 104–
106]. However, all three transcription factors also regulate
other aspects of EMT. For example, Snail and Slug regulate
tight junction stability [28], gap junctional protein expression
[107], desmosome disassembly [34] and protease expression
[108]. Indeed, Snail and Slug are expressed in response to
numerous EMT inducing stimuli including Wnt signaling
[109], Lbx1 [110], TGF-β signaling [111], loss of Sim2
expression [112], and hypoxia [113]. Similarly, Twist not
only represses E-cadherin, but also induces mesenchymal
gene expression and initiates invasion [35]. Like Snail and
Slug, Twist is the target of numerous EMT-inducing stimuli
including hypoxia and Msx2 [102, 114]. The convergence of
numerous EMT pathways on Snail, Slug and Twist suggest
that they are critical nodes in the network of EMT signaling.
J Mammary Gland Biol Neoplasia (2010) 15:117–134 127
Importantly, the association of Snail, Slug, and Twist
with EMT in vitro is also consistent with their observed
correlation with poor prognosis in human breast cancers. In
infiltrating ductal carcinoma, Snail expression correlates
with lymph node metastasis and with decreased relapse free
survival [115, 116], while Slug correlates with metastasis
[117]. Again, like Snail and Slug, Twist is associated with
adverse outcomes in breast cancer: it correlates with
invasive lobular carcinoma and decreased disease specific
survival [35, 117]. Overall, Twist, Snail and Slug all can
induce EMT in the context of normal tissue and cancer.
Importantly, in cancer the expression of these proteins
correlates with aggressive disease, reinforcing the pro-
metastatic effects of an oncogenic EMT.
The Six Family of Homeodomain Proteins
The E-cadherin repressors are not the only transcription
factors that play an important role during developmental
EMT and that are inappropriately expressed in breast
cancer. The Six family of homeodomain transcription
factors, specifically Six1, Six2 and Six4, are also important
during developmental EMT. For example, in muscle
development, the homeodomain transcription factors Six1
and Six4 regulate migration and cell fate determination of
muscle precursor cells [40, 118]. Specifically, the Six1/Six4
double knockout mouse exhibits a defect in the delamina-
tion and migration of muscle precursor cells, resulting in
the absence or hypoplasia of muscles [40] and underscoring
the importance of Six1 and Six4 in the EMT that occurs
during myogenesis. In kidney development, Six1 and Six2
are necessary for kidney formation [57, 58]. In particular,
Six2 maintains the mesenchymal phenotype of renal
progenitor cells and the downregulation of Six2 is
necessary for the MET observed as metanephric mesenchy-
mal cells transition into epithelial cells destined to form the
tubule epithelium. These data demonstrate that Six2 is an
important regulator of the mesenchymal state. Interestingly,
not only is Six2 critical in maintaining the mesenchymal
phenotype, but it is also necessary for maintaining the
nephrogenic progenitor cell population in the kidney,
reinforcing the link between a mesenchymal and a
progenitor/stem cell phenotype [58]. Importantly for this
review, the Six1 transcription factor is dynamically
expressed in the embryonic and postnatal mammary gland,
exhibiting its highest expression in the embryonic, neo-
natal, and pubertal mammary glands, after which its expres-
sion dramatically diminishes. Surprisingly, knockout of Six1
in the mammary gland does not appear to have a significant
functional consequence on mammary gland development.
However, due to the compensatory increase in Six2 and Six4
expression in response to Six1 loss, and thus the likelihood of
functional redundancy, the function of the Six family in
mammary gland development remains unclear [119]. In
addition to the role of the Six family members in epithelial
plasticity during muscle and kidney development, Six1
induces features of EMT in both a mammary carcinoma cell
line and in mammary tumors derived from mammary
specific Six1 overexpressing transgenic mice [36, 37].
Consistent with other regulators of EMT, Six1 also induces
metastatic spread in mouse models of tumor progression, and
analogous to the function of Six2 in development, Six1
overexpression induces properties of mammary and mam-
mary cancer stem/progenitor cells [36, 37]. The underlying
mechanism of Six1-induced EMT and metastasis appears to
be, at least in part, through the activation of TGF-β signaling
[37], a pathway that is well -established as a strong inducer
of EMT in breast cancer [31]. As seen with Snail, Slug, and
Twist, increased Six1 expression also correlates with poor
prognosis in breast cancer patients [37]. Patients with
elevated levels of Six1 have increased lymph node involve-
ment, shortened time to relapse and metastasis, and
decreased survival [37]. Together this work demonstrates
that misexpression of the Six1 developmental EMT regulator
in breast cancer induces an analogous EMT program in
tumor cells that contributes to tumor progression.
The Homeodomain Protein Lbx1
Although genes that play a role in mammary gland
development are misexpressed in breast cancer, so are
developmental regulators of EMT that are not known to be
involved in mammary gland development. Similar to the Six
family members, Lbx1 is a well established regulator of
muscle precursor migration and cell fate during development
[11, 120]. Recent work has shown that Lbx1 expression in
mammary carcinoma cells induces properties of EMT and
progenitor cells, activates known inducers of EMT, and
correlates with the basal subtype of human breast cancer
[110]. Together these results suggest that EMT programs
beyond those critical for mammary gland development may
be activated in human breast cancer and contribute to an
oncogenic EMT and breast cancer aggressiveness.
Sim2 Transcription Factor
In contrast to the inducers of EMT, inhibitors of epithelial
plasticity may be downregulated during development and
cancer, leading to an induction of a more mesenchymal
phenotype. Sim2 is a protein involved in mammary gland
development and breast cancer progression, likely through
its regulation of epithelial plasticity. Sim2 is a basic helix
loop helix/Per-Amt-Sim (bHLH/PAS) transcription factor
which has been identified as an important developmental
transcriptional repressor [121]. In the mammary gland, loss
of expression of the short isoform of Sim2 (Sim2s) disrupts
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both duct hollowing and morphogenesis, induces the
breakdown of the basement membrane, leading to the loss
of E-cadherin and apico-basal polarity, and results in the
invasion of epithelial cells into the surrounding stroma.
These changes are all consistent with Sim2 repressing
branching through the maintenance of an epithelial pheno-
type [112]. In the context of cancer, loss of Sim2 in
mammary carcinoma cells also induces an EMT as
measured by the loss of E-cadherin and concomitant gain
of vimentin and N-cadherin [112]. Importantly, Sim2 is lost
in the majority of breast cancers [122], suggesting that in
the absence of Sim2 breast cancer cells may be primed for
epithelial plasticity and EMT. Therefore, Sim2 is example
of a developmental mammary gland regulator of epithelial
plasticity that when lost in cancer induces features of EMT
which likely contribute to metastatic spread.
Developmental EMT Signaling Pathways Reactivated
in Breast Cancer
TGF-β Pathway
In addition to transcription factors, cell signaling pathways
are also critical inducers of EMT in the context of
development and in cancer. One of the best studied EMT
signaling pathways is TGF-β signaling. TGF-β is a
ubiquitously expressed cytokine that binds to a target cell
through the type I and II TGF-β receptors, initiating
multiple signaling cascades, including the canonical Smad
signaling pathway, that ultimately regulate transcription in
combination with cofactors [123]. During development,
TGF-β is required for heart valve formation, where TGF-
β2 activates the Type I receptor to induce an EMT and
permit the invasion of endocardial cells into the cardiac
cushions [124, 125]. Not only does TGF-β induce EMT in
heart development, but it also induces EMT during palato-
genesis, where TGF-β3 is required for palatal fusion [8,
126]. In vitro, TGF-β has been established as a classic
inducer of EMT in a wide range of systems [31]. The
consequences of TGF-β treatment are dramatic, leading to
a loss of apico-basal polarity [27], downregulation of cell-
cell adhesions [111], expression of mesenchymal cyto-
skeletal proteins including vimentin [127], as well as
extracellular proteases [128]. In breast cancer, TGF-β
signaling plays a dual role in tumorigenesis. In early lesions,
TGF-β is a significant tumor suppressor through its growth
inhibitory effects [129]. In contrast, TGF-β promotes
metastatic spread in later stages of tumorigenesis, likely at
least in part through its ability to induce EMT [85, 130, 131].
In numerous models of breast cancer associated invasion and
metastasis, activated TGF-β signaling induces increased
aggressiveness. For example, in mice overexpressing the
Neu oncogene, activated TGF-β signaling increases the
number of lung metastases even while decreasing the growth
of the primary tumor [131]. Likewise, ablation of TGF-β
signaling in the same model decreases lung metastasis while
also decreasing the latency of primary tumor growth, again
emphasizing the dual functions of TGF-β signaling in
tumorigenesis [85]. Additionally, clinical evidence suggests
a correlation between expression of the TGF-β ligands and
poor patient outcome [132, 133]. Furthermore, activated
TGF-β signaling has been observed in breast cancer bone
metastases and contributes to the establishment of these
lesions [134]. Because TGF-β signaling is critical for EMT
during cardiogenesis and palatogenesis, and because it also
promotes EMT in a tumorigenic context, it is likely that the
ability of TGF-β to promote metastasis is at least in part due to
of its ability to induce an EMT. For a more detailed
description of the role of TGF-β signaling in EMT, please
see the accompanying review by Schiemann and colleagues.
Wnt/β-catenin Pathway
Similar to the TGF-β pathway, the Wnt/β-catenin pathway is
also implicated in EMT and epithelial plasticity during
development and cancer. The Wnt pathway is activated
during multiple stages of mammary development from the
earliest stage during embryogenesis where Wnt signaling is
necessary for mammary bud formation, to the alveolar
differentiation and side branching observed during pregnancy.
Wnt signaling likely plays a role in numerous aspects of
mammary development including cell fate determination,
maintenance of mammary progenitor cell populations,
branching morphogenesis and alveolar differentiation [135].
Cells composing the TEB express multiple Wnt ligands and
receptors, consistent with a role for the Wnt pathway in
normal TEB function [67]. Indeed, misexpression of Wnt-1
under the control of the MMTV promoter induces hyper-
branching and precocious alveolar differentiation [136]. Not
only is the Wnt pathway important for normal mammary
development, but it also regulates EMT in other develop-
mental contexts including gastrulation and cardiac valve
formation [51, 137, 138]. Furthermore, in vitro studies con-
firm that the Wnt/β-catenin pathway is capable of inducing
epithelial plasticity. Activation of the Wnt pathway in
breast cancer cells induces the EMT regulator, Snail, and
upregulates the mesenchymal marker, vimentin [109, 139].
Additionally, the Wnt/β-catenin pathway induces EMT in
numerous models including mammary epithelial and
carcinoma cell lines [32, 109]. Importantly, markers
indicating active Wnt/β-catenin signaling, including nuclear
β-catenin, also correlate clinically in breast cancer patients
with poor prognosis [41, 42]. Taken together, these data
implicate the Wnt/β-catenin pathway in epithelial plasticity
and EMT in both development and cancer.
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The expression of these numerous developmental EMT
regulators in breast cancer, coupled with the induction of a
motile and mesenchymal phenotype in breast cancer cells in
response to the activation of these developmental genes and
pathways, establishes a significant parallel between develop-
ment and cancer. Most importantly, the significance of this
misexpression is revealed by the clear clinical implications
of the inappropriate activation of these genes and pathways.
In sum, the concept of an oncogenic EMT and its resem-
blance to developmental EMT is an important framework for
understanding the mechanisms of cancer metastasis and will
likely provide new therapeutic targets.
Conclusion
The spread of cancer cells from the primary tumor is a major
complicating factor of cancer progression, preventing effec-
tive treatment and substantially decreasing patient prognosis.
Only recently have we begun to understand the mechanism of
tumor cell spread and to identify potential therapeutic targets
to prevent or limit the extent of metastatic dissemination. As
the mechanisms of spread in epithelial-derived cancer are
becoming clear, similarities have been recognized to devel-
opmental programs of migration and invasion. These
similarities have led to the hypothesis that in tumorigenesis,
developmental pathways are activated inappropriately that
contribute to tumor progression. EMT is a critical mechanism
of migration and invasion during development. Recently
an analogous process has been observed in cancer cells
employing embryonic pathways as a mechanism to enhance
motility and invasion. Importantly, features of oncogenic
EMT correlate with clinical parameters, suggesting that
reactivation of the developmental EMT program in cancer
contributes to cancer progression. The reactivation of embry-
onic programs that are potentially not functional in normal
adult tissue provides an opportunity to selectively target these
pathways in cancer cells while conferringminimal side effects.
Future work will continue to investigate the parallels between
development and cancer and begin to consider oncogenic
EMT pathways as potential therapeutic targets.
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